A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations

被引：1
|
作者：
Lu, S. [1 ]
Zhou, J. [2 ]
Niu, X. [3 ]
Chen, M. [4 ]
Hua, Y. [4 ]
Su, W. [4 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Sch Med, Shanghai, Peoples R China
[2] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
[3] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China
[4] Hutchison Medipharma, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
Fruquintinib; non-small cell lung cancer; gefitinib;
D O I：
10.1016/j.jtho.2017.09.301
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
JCES 01.12
引用
收藏
页码：S1735 / S1735
页数：1
相关论文
共 50 条
  • [41] Outcomes in Latin American NSCLC patients harboring wild-type or activating mutations of EGFR (CLICaP Registry).
    Cardona Zorrilla, Andres Felipe
    Arrieta, Oscar
    Federico Bramuglia, Guillermo
    Delia Campos-Parra, Alma
    Becerra Ramirez, Henry Alberto
    MARCELO Claudio, Martin
    Richardet, Eduardo
    Serrano, Silvia J.
    Archila, Pilar
    Rosell, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [42] Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR
    Ahn, Myung-Ju
    Kim, Sang-We
    Cho, Byoung-Chul
    Ahn, Jin Seok
    Lee, Dae Ho
    Sun, Jong-Mu
    Massey, Dan
    Kim, Miyoung
    Shi, Yang
    Park, Keunchil
    ONCOLOGIST, 2014, 19 (07): : 702 - 703
  • [43] Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Single-Arm, Phase II Multi-Center Trial
    Park, S.
    Ahn, H. K.
    Lee, S.
    Min, Y. J.
    Jung, H. A.
    Sun, J. -M.
    Lee, S-H.
    Ahn, J. S.
    Ahn, M. -J.
    Lee, J. B.
    Kim, S. M.
    Kim, H. R.
    Cho, B. C.
    Hong, M. H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S148 - S149
  • [44] Neoadjuvant erlotinib in stage III NSCLC patients (pts) with activating EGFR mutations (EVENT trial).
    Inal, Cengiz
    Piperdi, Bilal
    Keller, Steven M.
    Halmos, Balazs
    Stoopler, Mark
    Limaye, Sewanti Atul
    Levy, Benjamin Philip
    Schneider, Bryan J.
    Kim, Mimi
    Sides, Jessica
    Perez-Soler, Roman
    Cheng, Haiying
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] EGFR Mutation Status in NSCLC Patients Stage IIIB/IV in Germany - Initial Results From a German Registry
    Thomas, M.
    Eberhardt, W.
    von der Schulenburg, J. M. Graf
    Dietel, M.
    Schirmacher, P.
    Gutendorf, B.
    Zirrgiebel, U.
    Schuette, W.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S596 - S596
  • [46] Thoracic Radiotherapy and Concurrent Gefitinib in Patients with IIIB/IV Non-small Cell Lung Cancer (NSCLC): Phase I Study
    Zhang, G.
    Xie, L.
    Xu, X.
    Chen, J.
    Fu, X.
    Jiang, G.
    Fan, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S455 - S455
  • [47] LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
    Garrido, Pilar
    Paz-Ares, Luis
    Majem, Margarita
    Moran, Teresa
    Trigo, Jose Manuel
    Bosch-Barrera, Joaquim
    Garcia-Campelo, Rosario
    Gonzalez-Larriba, Jose Luis
    Sanchez-Torres, Jose Miguel
    Isla, Dolores
    Vinolas, Nuria
    Camps, Carlos
    Insa, Amelia
    Juan, Oscar
    Massuti, Bartomeu
    Paredes, Alfredo
    Artal, Angel
    Lopez-Brea, Marta
    Palacios, Jose
    Felip, Enriqueta
    CANCER MEDICINE, 2021, 10 (17): : 5878 - 5888
  • [48] A Phase II Study of Gefitinib With Concurrent Thoracic Radiotherapy in Patients With Unresectable, Stage III Non-small-cell Lung Cancer Harboring EGFR Mutations (WJOG6911L)
    Akamatsu, Hiroaki
    Harada, Hideyuki
    Tokunaga, Shoji
    Yoshimura, Naruo
    Ikeda, Hiroko
    Oizumi, Satoshi
    Sugimoto, Naotoshi
    Takano, Toshimi
    Murakami, Haruyasu
    Nishimura, Yasumasa
    Yamamoto, Nobuyuki
    Nakagawa, Kazuhiko
    CLINICAL LUNG CANCER, 2019, 20 (01) : E25 - E27
  • [49] Neoadjuvant gefitinib for stage II-IIIA NSCLC with activating EGFR mutation (NCT01833572): an open-label, single-arm, phase II study.
    Gongt, Ranxia
    Hu, Haichuan
    Chen, Haiquan
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [50] A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinonna harboring EGFR mutations
    Kim, Dong-Wan
    Lee, Se-Hoon
    Lee, Jong Seok
    Lee, Myung Ah
    Kang, Jin Hyoung
    Kim, Si Young
    Shin, Sang Won
    Kim, Hoon-Kyo
    Heo, Dae Seog
    LUNG CANCER, 2011, 71 (01) : 65 - 69
12345